ArriVent BioPharma, Inc. AVBP Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s total liabilities & equity?
- ArriVent BioPharma, Inc. (AVBP) reported total liabilities & equity of $349.3M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total liabilities & equity changed year-over-year?
- ArriVent BioPharma, Inc.'s total liabilities & equity increased by 62.1% year-over-year, from $215.5M to $349.3M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total liabilities & equity?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total liabilities & equity has grown at a 42.9% compound annual growth rate (CAGR), from $163.1M to $333.17M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.